Who Generates More Revenue? Genmab A/S or Mesoblast Limited

Genmab A/S dominates revenue over Mesoblast Limited.

__timestamp	Genmab A/S	Mesoblast Limited
Wednesday, January 1, 2014	850385000	25980000
Thursday, January 1, 2015	1133041000	23748000
Friday, January 1, 2016	1816122000	42548000
Sunday, January 1, 2017	2365436000	2412000
Monday, January 1, 2018	3025137000	17341000
Tuesday, January 1, 2019	5366000000	16722000
Wednesday, January 1, 2020	10111000000	32156000
Friday, January 1, 2021	8482000000	7456000
Saturday, January 1, 2022	14595000000	10211000
Sunday, January 1, 2023	16474000000	7501000
Monday, January 1, 2024		5902000

Unlocking the unknown

Revenue Showdown: Genmab A/S vs. Mesoblast Limited

In the dynamic world of biotechnology, revenue generation is a key indicator of a company's market prowess. Over the past decade, Genmab A/S has consistently outperformed Mesoblast Limited in terms of revenue. From 2014 to 2023, Genmab's revenue surged by over 1,800%, peaking at approximately $16.5 billion in 2023. In contrast, Mesoblast's revenue remained relatively modest, with a peak of around $42.5 million in 2016, and a decline to about $7.5 million by 2023.

This stark contrast highlights Genmab's strategic advancements and market penetration, while Mesoblast faces challenges in scaling its operations. The data from 2024 is incomplete, but the trend is clear: Genmab A/S has established itself as a revenue powerhouse in the biotech sector, leaving Mesoblast Limited trailing behind.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025